An advisory committee from the Food and Drug Administration (FDA), which includes members connected to the industry, has recommended easing regulations on six peptides. This decision followed objections from FDA scientists concerned about the inadequate data supporting these compounds.
Peptides are marketed for various benefits, such as faster healing, youthful skin, and longer lifespans. However, there is little evidence confirming their effectiveness and safety. Despite these concerns, the FDA panel suggested that two additional peptides could be compounded, adding to the existing list.
This recommendation concluded a two-day meeting, sparking discussions about whether the FDA’s measures to prevent untested drugs from reaching consumers are being weakened.
Political Strategies and Medicare-for-All Debate 
Exploring the Off-Label Use of Tadalafil for Longevity 
Transgender Youth and Medicaid: Navigating New Challenges 
The Silicosis Threat in California’s Engineered-Stone Industry 
Arizona Mother Navigates Extraordinary Dietary Needs for Her Son with Rare Disorder 
Chronic Pain Shouldn’t Be Overlooked in Rising Temperature Concerns